Tolterodine ER 4mg + Placebo + Pre-randomization Dutasteride
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Benign Prostatic Hyperplasia (BPH)
Conditions
Benign Prostatic Hyperplasia (BPH)
Trial Timeline
Jul 1, 2009 → Sep 1, 2014
NCT ID
NCT00939120About Tolterodine ER 4mg + Placebo + Pre-randomization Dutasteride
Tolterodine ER 4mg + Placebo + Pre-randomization Dutasteride is a approved stage product being developed by Pfizer for Benign Prostatic Hyperplasia (BPH). The current trial status is completed. This product is registered under clinical trial identifier NCT00939120. Target conditions include Benign Prostatic Hyperplasia (BPH).
What happened to similar drugs?
9 of 20 similar drugs in Benign Prostatic Hyperplasia (BPH) were approved
Approved (9) Terminated (2) Active (9)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00939120 | Approved | Completed |
Competing Products
20 competing products in Benign Prostatic Hyperplasia (BPH)